RecruitingPhase 2psilocybin
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Sponsored by COMPASS Pathways
NCT ID
NCT07570654
Target Enrollment
300 participants
Start Date
2026-09-14
Est. Completion
2029-09
About This Study
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Conditions Studied
Interventions
- •COMP360 psilocybin
Eligibility
Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * 18 years or older * Diagnosed with PTSD at least 6 months ago Exclusion Criteria: \- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions
Study Locations (17)
AZ
Tucson, Arizona, United States
CA
Irvine, California, United States
CA
Los Angeles, California, United States
CA
Moorpark, California, United States
FL
Miami, Florida, United States
FL
Orlando, Florida, United States
IL
Chicago, Illinois, United States
MA
Boston, Massachusetts, United States
MN
Eden Prairie, Minnesota, United States
NE
Lincoln, Nebraska, United States
+7 more locations